{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T22:37:12Z","timestamp":1777415832491,"version":"3.51.4"},"reference-count":42,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2002,12,18]],"date-time":"2002-12-18T00:00:00Z","timestamp":1040169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2003,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>One of the mechanisms of action of cladribine is the inhibition of DNA repair of damage caused by radiation, alkylating agents, or other drugs. To determine its antitumor activity in combination with cyclophosphamide, we initiated a Phase II trial of the two agents in patients with advanced chronic lymphocytic leukemia (CLL) or prolymphocytic leukemia (PLL).<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Twenty\u2010nine patients with refractory or recurrent CLL or PLL received cladribine 4 mg\/m<jats:sup>2<\/jats:sup>\/day and cyclophosphamide 350 mg\/m<jats:sup>2<\/jats:sup>\/day (both administered intravenously) for 3 days every 4 weeks.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>Eleven patients (38%), nine with CLL and two with PLL, had a response. The median duration of response was 12 months. Severe extrahematologic toxicity (National Cancer Institute Grade 3\u20134) occurred in two patients, consisting of skin rash in one patient and progressive multifocal leukoencephalopathy in the other. The most common form of hematologic toxicity was severe neutropenia, which developed after 25% of the 84 courses was administered. Severe thrombocytopenia and anemia developed after 12% and 7% of the courses, respectively, and five episodes of anemia were immunomediated. In addition, three major infections resulted in the death of one patient.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>Although inferior to the combination fludarabine plus cyclophosphamide, this regimen showed interesting activity in patients with advanced CLL or PLL. Myelosuppression was the major dose\u2010limiting toxic effect. Cancer 2003;97:114\u201320. \u00a9 2003 American Cancer Society.<\/jats:p><jats:p>DOI 10.1002\/cncr.11000<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.11000","type":"journal-article","created":{"date-parts":[[2002,12,19]],"date-time":"2002-12-19T08:57:58Z","timestamp":1040288278000},"page":"114-120","source":"Crossref","is-referenced-by-count":62,"title":["Phase II study of cladribine and cyclophosphamide in patients with chronic lymphocytic leukemia and prolymphocytic leukemia"],"prefix":"10.1002","volume":"97","author":[{"given":"Marco","family":"Montillo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Tedeschi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"O'Brien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco Di","family":"Raimondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Lerner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Ferrajoli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrica","family":"Morra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Keating","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2002,12,18]]},"reference":[{"key":"e_1_2_5_2_2","first-page":"152","article-title":"Fludarabine phosphate in lymphoma: an important new therapeutic agent","volume":"29","author":"McLaughlin P","year":"1988","journal-title":"Am J Hematol."},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(91)80164-H"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(93)90231-D"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/7.suppl_6.S27"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.6.1918"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1996.14.7.2160"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1993.11.1.116"},{"key":"e_1_2_5_9_2","first-page":"2","article-title":"Fludarabine and cyclophosphamide: synergistic cytotoxicity associated with inhibition of interstrand cross\u2010link removal","volume":"38","author":"Koehl U","year":"1997","journal-title":"Proc Am Assoc Cancer Res."},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V94.8.2836.420k35_2836_2843"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-642-71960-8_73"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1008376728894"},{"key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1182\/blood.V46.2.219.219","article-title":"Clinical staging of chronic lymphocyte leukemia","volume":"46","author":"Rai KR","year":"1975","journal-title":"Blood."},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V87.12.4990.bloodjournal87124990"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V"},{"issue":"1","key":"e_1_2_5_17_2","first-page":"313a","article-title":"Fludarabine plus cyclophosphamide (FC) and dose intensified chlorambucil (DIC) for the treatment of chronic lymphocytic leukemia: results of two phase II studies (CLL\u20102protocol) of the German CLL Study Group (GCLLSG)","volume":"94","author":"Hallek M","year":"1999","journal-title":"Blood."},{"key":"e_1_2_5_18_2","first-page":"457","article-title":"Fludarabine monophosphate: a potentially useful agent in chronic lymphocyitic leukemia","volume":"30","author":"Grever MR","year":"1988","journal-title":"Nouv Rev Fr Hematol."},{"issue":"8","key":"e_1_2_5_19_2","first-page":"49","article-title":"Fludarabine phosphate in the treatment of chronic lymphocytic leukemia","volume":"17","author":"Keating MJ","year":"1990","journal-title":"Semin Oncol."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91681-5"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1997.15.2.458"},{"key":"e_1_2_5_22_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19851115)56:10<2369::AID-CNCR2820561004>3.0.CO;2-N"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199009069292"},{"key":"e_1_2_5_24_2","first-page":"1110","article-title":"Combination chemotherapy of advanced chronic lymphocytic leukemia: the M\u20102 protocol (vincristine, BCNU, cyclophosphamide, melphalan, and prednisone)","volume":"60","author":"Kempin S","year":"1982","journal-title":"Blood."},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.7.2463.2463"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2001.19.5.1414"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2001.02959.x"},{"key":"e_1_2_5_28_2","first-page":"1829","article-title":"2\u2010Chlorodeoxyadenosine therapy in chronic lymphocytic leukemia","volume":"330","author":"Saven A","year":"1994","journal-title":"N Engl J Med."},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401095"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199210083271504"},{"key":"e_1_2_5_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V84.3.733.733"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199303183281116"},{"key":"e_1_2_5_33_2","first-page":"1130","article-title":"2\u2010Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"9","author":"Delannoy A","year":"1995","journal-title":"Leukemia."},{"key":"e_1_2_5_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2401783"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1999.01212.x"},{"key":"e_1_2_5_36_2","first-page":"1290","article-title":"Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia","volume":"8","author":"Weiss M","year":"1994","journal-title":"Leukemia."},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200012143432402"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6690195"},{"issue":"3","key":"e_1_2_5_39_2","first-page":"22","article-title":"Clinical challenges in chronic lymphocytic leukemia","volume":"35","author":"O'Brien S","year":"1998","journal-title":"Semin Hematol."},{"key":"e_1_2_5_40_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.2830490207"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2400816"},{"key":"e_1_2_5_42_2","doi-asserted-by":"publisher","DOI":"10.3109\/10428199109068099"},{"key":"e_1_2_5_43_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.0952e.x"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.11000","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.11000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T17:20:34Z","timestamp":1760289634000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.11000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,12,18]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2003,1]]}},"alternative-id":["10.1002\/cncr.11000"],"URL":"https:\/\/doi.org\/10.1002\/cncr.11000","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2002,12,18]]}}}